Dendreon Interest Remains Extremely High
by Jon C. Ogg
247 Wall St.
Since Dendreon (DNDN) has gotten a bit of life this week, there have been numerous inquiries as to “Where is this stock going?” from stock investors.
There is obviously some hope by investors that the activists will be able to push the FDA into approving Provenge for late-stage prostate cancer. The fact that an activist group has started Provengenow.org probably says it all. It is not yet known who started Provengenow.org’s web site because the registrar is actually “MyPrivateRegistration” if you look up the domain owner. This web site has actually become more full with more data even since yesterday. What is becoming more obvious is that Dendreon “may” find itself as winner because of “cancer patient activism” rather than investor activism. This activist group was also noted yesterday on CNBC and this helped the bullish scenario’s fight yesterday.
Continue article at 247WallSt.com
RELATED READING:
- Dendreon’s New Double-Twist
- Dendreon, the Day That Could Have Been and What to Expect Now
- Rantasorous Rx
___________________
Comments
Leave a Reply
You must be logged in to post a comment.